The ZNF198/FGFR1 fusion kinase associated with an atypical myeloproliferative disease is constitutively activated and regulates several STAT transcription factors. We used oligonucleotide microarrays to compare the gene expression profiles between HEK-293 cells that stably express either the ZNF198/FGFR1 chimeric protein or the wild-type ZNF198 gene.
INTRODUCTION
Reciprocal chromosomal translocations in hematological malignancies often result in the generation of novel fusion proteins. These chimeric proteins generally provide novel signaling functions which are considered to account for the oncogenic events in the leukemic cells 1 . One such chromosomal translocation was described in patients with an atypical form of myeloproliferative disease (MPD) that is associated with T cell leukemia/lymphoma and peripheral blood eosinophilia 2 and involves a reciprocal t(8;13)(p11;q12) rearrangement [3] [4] [5] [6] [7] [8] . In this translocation a zinc finger gene, ZNF198, is fused in-frame with the fibroblast growth factor receptor 1 (FGFR1). The resultant protein contains the zinc finger motif and proline-rich domain of ZNF198 and the intracellular tyrosine kinase domain of FGFR1 [9] [10] [11] [12] . The resulting ZNF198/FGFR1 fusion protein is a ligand independent, constitutively active cytoplasmic tyrosine kinase, unlike FGFR1 which is a membrane-bound receptor tyrosine kinase. Although the signaling functions of the ZNF198/FGFR1 fusion kinase were proposed based on the functions of FGFR1, the fusion kinase has been suggested to have unique signaling functions which are different from FGFR1 because of its cytoplasmic localization and constitutive tyrosine kinase activity [13] [14] . The oncogenic potential of the ZNF198/FGFR1 fusion kinase was demonstrated in IL-3 dependent Ba/F3 cells, where stable expression of the chimeric fusion protein produced IL-3 independent growth [15] [16] [17] . While activation of FGFR1 is known to result from dimerization following ligand binding, the ZNF198/FGFR1 fusion kinase is activated through homodimerization of the ZNF198 zinc finger domain [14] [15] [16] .
ZNF198 is a widely expressed gene that encodes a 1377-amino acid nuclear protein with a molecular mass of 155 kd [9] [10] [11] [12] . Prominent features of ZNF198 are the five zinc finger motifs and a proline rich domain (PRD) within the central part of the protein and an acidic domain at the For personal use only. on . by guest www.bloodjournal.org From C-terminal end of the protein 9 . Based on the structure and the type of zinc fingers present in ZNF198, it has been predicted to have a function in protein-protein interactions. A putative nuclear localization signal (NLS) is located in the C-terminal end of the ZNF198 protein, which is lost in the ZNF198/FGFR1 fusion protein. It is thought that the predominantly cytoplasmic localization of ZNF198/FGFR1 results from loss of the NLS.
Although it is generally assumed that the ZNF198/FGFR1 protein is responsible for the transformed phenotype in MPD, it is also possible that the cytoplasmic localization of the fusion protein may act in a dominant negative way on the ZNF198 protein, since the two proteins can dimerize through the zinc finger motif 14 . Apart from its dimerization role in the fusion gene, however, little is known about the normal function of ZNF198. Recently, we reported that ZNF198 interacts with the HHR6A/6B and RAD18 proteins that are involved in the postreplication DNA repair process 18 . The ZNF198/FGFR1 fusion protein, however, only interacted with the HHR6A/6B proteins and not with HRAD18, which is essential for the DNA repair function. As a result, cells expressing the ZNF198/FGFR1 chimeric protein showed a reduced capacity to repair UV-radiation induced DNA damage 18 .
ZNF198/FGFR1-mediated signaling mimics that of ligand-activated FGFR1, in that both activate the signal transduction proteins STAT1, STAT3 and STAT5 14 . The activation of STAT proteins in the presence of ZNF198/FGFR1 has also been observed in different cell types such as BaF3, HepG2, Cos7 and HEK-293 11, 14, 19 , demonstrating that ZNF198/FGFR1 mediates the activation of these proteins irrespective of the cell type used. In the case of ZNF198/FGFR1
signaling, the activation of the STAT proteins was shown to be more potent and ligand independent. It has also been demonstrated that the ZNF198/FGFR1 protein shows the signaling functions comparable to those of the interleukin-6 cytokine receptors 14 . To investigate potential dysregulation of gene activity in cells expressing the ZNF198/FGFR1 fusion protein, we generated several HEK-293 cell clones with constitutive activation of the fusion gene 14, 18 . RNA from these cells was used to screen the Affymetrix U133A oligonucleotide array. A consistent finding between different clones was the highly up-regulated expression of the plasminogen activator inhibitor-2 (PAI-2 /SERPINB2) gene compared with the parental HEK-293 cells which did not show any detectable PAI-2 expression. The same upregulation of PAI-2 was also seen in ZNF198/FGFR1 expressing BaF/3 hematopoietic cells. In both cases the cells are resistant to TNF /CHX-mediated cytotoxicity, only when the PAI-2 gene is activated.
MATERIALS AND METHODS

Constructs
The chimeric ZNF198/FGFR1 fusion gene was amplified by PCR from leukemic cells expressing the fusion gene. The PCR product was then cloned into the pEGFP-C2 vector as an N-terminal GFP fusion gene. The full length ZNF198 gene was amplified from a fetal bone marrow cDNA library and similarly cloned into the pEGFP-C2 vector. The full length FGFR1 gene was amplified from HEK-293 cDNA and cloned into the pCDNA3 vector.
Cell culture and Transfection studies
HEK-293 cells were maintained in DMEM with 10% FBS in 5% CO 2 and were used to establish cells stably expressing the ZNF198 or the ZNF198-FGFR1 fusion kinase. Transfections were performed using lipofectamine (Invitrogen, Carlsbad, CA) as described earlier 18 . Cells were transferred 48h after transfection into DMEM containing 10% FBS and 500µg/ml of G418.
Green colonies were identified using a flourescence microscope and isolated using ring cloning.
BaF/3 cells were routinely maintained in RPMI-1640 containing 10%FBS (complete medium) with 1 ng/ml of IL-3. Transfection into these cells was achieved by electroporation. Briefly, 5 X 6 cells were washed three times in 1X PBS, mixed with 20µg of linearized ZNF198/FGFR1
plasmid and electroporated using a Bio-Rad gene pulser set at 300V and 975µF. Cells were transferred into complete medium. After 48 hours, 1.0 mg/ml of G418 was added to the culture.
Individual green flourescent clones were isolated by limiting dilution into 96 well plates.
Specific gene expression was confirmed using RT-PCR and protein expression was confirmed by western blotting using an anti-GFP monoclonal antibody (Covance, NJ). Detection of the secreted form of PAI-2 was determined by western blotting as described below.
RT-PCR analysis
RNA from cell cultures was prepared using the Trizol (Invitrogen, Carlsbad, CA) method as described previously 20 . The purity of the RNA was determined colorimetrically. The
SuperScript One-step RT-PCR kit (Invitrogen, Carlsbad, CA), with platinum Taq, was used to amplify RNA in the samples. For PAI-2, the primer set used was;
human PAI-2:
forward-5'-CAGATGAAATTGCCGATGTG-3' reverse-5'CCATGTCCAGTTCTCCCTGT-3' which gives a 346bp product.
Mouse PAI-2:
forward-5' -CACCACAGGGGGATTATTTG reverse-5' -GGATGCGTCCTCAATCTCAT which gives a 482bp product.
Gene Expression analysis
RNA extracted from individual HEK-293 cell clones was used to prepare cRNA for hybridization to the Affymetrix U133A oligonucleotide arrays as described previously 20, 21 . The gene expression profile from the ZNF198/FGFR1 expressing cells was compared with that obtained from HEK-293 clones stably expressing the GFP protein from the pEGFP vector. To
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After the genes were sorted using a count and percent tool a list of only those that showed altered expression in at least 2 of the ZNF198/FGFR1 clones (2 cross-comparisons) was compiled. A cut-off of an average 2-fold or greater change was selected. All functional annotation and chromosomal locations were obtained using NetAffx 22 .
Immunoprecipitations and western blotting
Cells grown to 80% confluency were washed twice with PBS and lysed in RIPA buffer (50mM Tris containing 150mM NaCl 0.1% SDS 1% TritonX-100 1% sodium deoxycholate pH7.2) with 0.2% protease and phophatase inhibitor cocktails (Sigma, MO) on ice for 10 min. 
DNA Fragmentation analysis
Cells were plated in 6-well plates and after 24 hours were treated with TNF-(10ng/ml) and cycloheximide (1µg/ml) overnight at 37 0 C. The cells were then harvested and resuspended in lysis buffer (25mM Tris-HCl pH 8.0, 500mM NaCl, 4mM EDTA, 0.5% SDS and 0.5%
TritonX-100). The cell lysate was incubated with RNase (0.2mg/ml) overnight at room temperature and then with proteinase K (1mg/ml) for 1hr at 37 0 C. DNA was precipitated with 75% cold ethanol and the pellet was recovered at 14000 X g for 10 min and then air-dried and dissolved in 20µl of Tris-EDTA buffer (10mM Tris-HCl, pH 8.0 containing 1mM EDTA). This preparation was used for DNA fragmentation analysis by electrophoresis through a 1% agarose gel and the DNA fragments were visualized with ethidium bromide under UV.
Stepwise separation of Nuclear and cytoplasmic extracts from cells
Preparation of cytoplasmic and nuclear extracts was achieved by using NE-PER nuclear and cytoplasmic extraction reagents purchased from Pierce, IL. Briefly, cells were harvested and washed twice with cold PBS. Cold cytoplasmic extraction reagent I (CER I) was mixed with 0.2% protease inhibitor cocktail (Calbiochem, CA) and added to the cell pellet at a volume of 1ml CER I per 100µl of the packed cell volume. The tube was vigorously vortexed for 15 sec. and the cell suspension was left on ice for 10 min. 55µl of cold cytoplasmic extraction reagent II (CER II) was added to the suspension, vortexed vigorously for 5 sec. and left on ice for 1min.
The tube was again vortexed and centrifuged at 16,000 xg for 5min. The supernatant was collected and used as the cytoplasmic fraction. The insoluble pellet was resuspended in 500µl cold nuclear extraction reagent (NER) containing 0.2% protease inhibitor cocktail. The tube was vortexed for 15sec. Sample was left on ice and vortexed for 15 sec. every 10 min for a total of 40 min. The sample was centrifuged at 16,000 X g and the supernatant was collected and used as
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Chromogenic assay for the effect of PAI-2 on uPA activity:
The PAI-2 chromogenic assay measures the release of a specific chromophore from its substrate in the presence of uPA. The assay was performed in 96 well plates to determine the activity of uPA in presence of various culture supernatants. Standard uPA, plus substrate, was used to establish the baseline level of its activity. When commercial, purified PAI-2 is added to this reaction >99% inhibition is seen. The uPA activity in the presence of various cell culture supernatants was compared to these standards and expressed as relative OD to assess the level of inhibition. When cell cultures reached 80% confluence, fresh serum free medium was added and then these culture supernatants were collected after 24h and concentrated using Amicon concentrators. Protein levels were measured using Bradford reagent (Pierce, IL). Different concentrations of the protein were incubated at 37 o C in 10mM HEPES buffer, pH 7.4, containing 5 IU of human high molecular weight uPA, 50ug/ml of human Glu-plasminogen and 1mM chromogenic substrate, Spectrozyme PL (H-D-norleucyl-hexahydrotyrosol-lysine-paranitroanilide diacetate). uPA, Plasminogen and Spectrozyme PL were obtained from American Diagnostica, CT. Reactions were performed for 30 min and the release of free p-nitoraniline from the chromogenic substrate was measured at 415nM using a Bio-Rad Benchmark Plate reader.
RESULTS
The ZNF198/FGFR1 fusion kinase has been shown to regulate the activation of members of the STAT family of transcription factors 14 and so clearly affects the gene expression profile of cells expressing it. We have previously generated HEK-293 cells which stably express a GFPtagged ZNF198/FGFR1 chimeric gene as well as a wild-type ZNF198 gene 14, 18 . To investigate the nature of gene expression changes as a result of expression of the ZNF198/FGFR1 fusion protein, we used the Affymetrix U133A oligonucleotide arrays to compare expression profiles between clones from these two stable transfectants with those expressing GFP alone. To confirm that the individual clones expressed the correctly sized proteins, we used western blotting 14, 18 .
Analysis of oligonucleotide microarrays
cRNA from two different clones was hybridized to the U133A chips. After baseline correction, the data were arbitrarily filtered to display only those genes that were at least 2-fold (table 1) . For example, pigment epithelium derived factor (PEDF/SERPINF1), which is known to enhance cellular differentiation, was down-regulated 11-fold in ZNF198/FGFR1 expressing cells. HSP47, (SERPINH1, also called collagen binding protein), was decreased 7-fold in ZNF198/FGFR1 expressing cells compared to control cells. PAI-2, which is not expressed at detectable levels in 293 cells expressing GFP alone, was apparently induced at high levels in ZNF198/FGFR1 expressing cells. PAI-2 is one of the members of the well-known urokinase plasminogen (uPA) activation system, which has been shown to play an important role in tumor growth, invasion and metastasis Interestingly, the expression profile of the other components of the uPA system, namely PAI-1 (SERPINE1), uPA, and its receptor (uPAR), was not altered in ZNF198/FGFR1 expressing cells.
Analysis of PAI-2 expression in ZNF198/FGFR1 expressing cells
Among the SERPIN family, PAI-2 showed the highest upregulation in our analysis and has also been shown to be upregulated in certain myeloproliferative diseases and leukemias 23 .
This finding prompted us to focus further on the role of PAI-2 upregulation in ZNF198/FGFR1 fusion kinase-expressing cells. RT-PCR and western blot analyses were used to analyze HEK-293 cells which expressed GFP, ZNF198 or ZNF198/FGFR1. Detectable levels of PAI-2 were only present in the ZNF198/FGFR1-expressing cells ( Figure 1A ). Western blot analysis of cell extracts confirmed that only the cells expressing ZNF198/FGFR1 contained the PAI-2 protein ( Figure 1B) . All of the different clones expressing ZNF198/FGFR1 also expressed PAI-2 in relatively proportional amounts. In our earlier report 14 , we observed that ZNF198/FGFR1
expressing cells tended to lose the fusion gene after various lengths of time in culture. This meant that we must constantly subclone to maintain high levels of expression in the overall population. It is likely, therefore, that the two clones (4 and 5) which show lower levels of both ZNF198/FGFR1 and PAI-2 expression, are in the process of losing the fusion kinase.
Interestingly, all these clones expressed two molecular forms of PAI-2; one which was 47kd that is expressed in many different cell types, and the other which was approximately 32kd. It has been reported previously that PAI-2 is degraded under conditions of induced apoptosis, although the break down product still remains active as a uPA inhibitor 24, 25 . In our experiments, it was apparent, however, that in clones expressing low levels of ZNF198/FGFR1, the reduction of the 32 kd product was disproportionate relative to the 47 kd protein.
To determine whether expression of ZNF198/FGFR1 induces expression of PAI-2 in It has been shown that the ZNF198/FGFR1 encodes a protein which has a kinase function similar to that of FGFR1. However, unlike the product of the intact endogenous FGFR1, this chimeric protein is an intracellular (non-membrane bound), constitutively active kinase which can constitutively activate the STAT signaling pathway 14 . To determine whether FGFR1-mediated signaling is responsible for the induction of PAI-2 expression, HEK-293 cells were transfected with a full length FGFR1 gene and stable exogenous FGFR1 expressing clones were isolated.
When these cells were stimulated with bFGF (10ng/ml in the presence of 100U of heparin), RNA and protein analysis demonstrated that PAI-2 expression is not induced ( Figure 1D ).
Phosphorylation of FGFR1, however, was observed in these cells following bFGF treatment ( Figure 1D ), indicating that the FGFR1 protein undergoes standard activation. These results demonstrate that neither ZNF198 expression, nor membrane initiated FGFR1 activation, alone could induce the expression of PAI-2 in HEK-293 cells. Thus, PAI-2 induction seems to represent a unique consequence of the signaling events associated with the expression of the constitutively active ZNF198-FGFR1 fusion kinase.
Subcellular localization of PAI-2 in ZNF198/FGFR1 expressing cells
To determine the localization of PAI-2 in cells expressing the ZNF198/FGFR1 fusion gene, the culture supernatants from these cells were analyzed for the presence of the PAI-2
protein. Western blot analysis demonstrated that a 60 kd glycosylated form of PAI-2 is secreted by ZNF198/FGFR1 expressing cells (Figure 2A ) but not by cells expressing the wild-type ZNF198 or GFP alone. PAI-2 was also not secreted in cells expressing FGFR1 after treatment with bFGF. Although it is well established that PAI-2 can be either cytoplasmic or secreted into
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From the extracellular mileu, recent studies also point to a function for PAI-2 in the nucleus 26 . To determine whether this holds true for HEK-293 cells, cytoplasmic and nuclear extracts were prepared using NE-PER extraction reagents (Pierce, Rockford, IL) and analyzed by western blotting. These results demonstrated that both the 47kd and 32kd forms of the PAI-2 protein are predominantly in the cytoplasm in ZNF198/FGFR1-expressing HEK-293 cells ( Figure 2B ).
Measurement of uPA inhibitory activity in culture supernatants:
PAI-2 was originally shown to be an inhibitor of urokinase, which converts plaminogen to plasmin. We showed above that PAI-2 is secreted into the culture medium by ZNF198/FGFR1 expressing HEK-293 cells. To further determine whether the PAI-2 protein that is produced in cells expressing the fusion kinase was functional in terms of its activity as a uPA inhibitor, we collected supernatants from HEK-293 cells expressing the ZNF198/FGFR1 chimeric protein and compared their ability to inhibit plasminogen conversion with the similarly processed supernatants from cells expressing either GFP or ZNF198 which do not express PAI-2.
The supernatants were concentrated using Amicon concentrators and chromogenic assay was performed using different concentrations of protein from the supernatants (figure 3). A fixed concentration of both uPA (5 IU) and plasminogen (50µg/ml), as well as a fixed 1mM substrate was used in each assay. As shown in figure 3 , when increasing concentrations of the culture supernatant was used, no change in chromophore release was seen in the presence of protein obtained from supernatants from GFP-or ZNF198-expressing cells compared to the uPA standard alone. In contrast, there is a dose-dependent increase in the inhibition of uPA mediated chromophore release in the presence of supernatants from cells expressing ZNF198/FGFR1.
These analyses demonstrate that the secreted PAI-2 protein in the cells expressing the fusion kinase can inhibit the function of uPA.
For
Co-Immunoprecipitation analysis
As described above, PAI-2 was induced only in cells that expressed the ZNF198/FGFR1 
Analysis of TNF-induced cytotoxicity in ZNF198/FGFR1-293 cells
TNF-has been shown to induce the expression of PAI-2 on its own 27, 28 , and also has diverse effects on cells, some of which are related to PAI-2 expression. For example, in the absence of new protein synthesis following treatment of cells with cycloheximide, PAI-2 induces resistance to TNF-mediated cytotoxicity 29 . We therefore determined whether PAI-2 expression in ZNF198/FGFR1-expressing cells correlates with resistance of these cells to TNFmediated cytotoxicity. Treatment of GFP-expressing HEK-293 cells with TNF-alone induced the expression of PAI-2 ( Figure 5A ). These cells, however, contained only the 47kd form of the protein in the cytoplasm. In contrast, the ZNF198/FGFR1-expressing cells possessed both the 47kd as well as a 32kd proteins in the cytoplasm. TNF-treatment, in the presence of cycloheximide (1µM), induced a potent apoptosis in both HEK-293 cells expressing either GFP or ZNF198 ( Figure 5B ), but not in ZNF198/FGFR1-expressing cells. BaF/3 cells expressing ZNF198/FGFR1 also showed a resistance to TNF mediated apoptosis that was not present in the parental BaF/3 cells ( Figure 5C ). This analysis demonstrates that PAI-2 expression in ZNF198/FGFR1-expressing cells correlates with resistance to TNF-mediated apoptosis.
DISCUSSION
The ZNF198/FGFR1 fusion gene 9 , that is associated with an atypical MPD, generates a chimeric protein with constitutive intracellular tyrosine kinase activity. Since the t(8;13)
translocation that produces this fusion kinase gene occurs often as the only cytogenetic change in the leukemic cells, it is assumed that the fusion gene acts as a dominant oncogenic event. 30 .
PAI-2 belongs to the sub-group of serpins known as the ovalbumin-like serine proteinase inhibitors [31] [32] [33] . Within this subgroup, it is a member of the urokinase-type plasminogen activator inhibitor (uPA) system that converts plasminogen to plasmin. This event often facilitates cell migration and invasion by both degrading fibrin and activating metalloproteinases 34, 35 . The uPA system also plays a major role in tumor growth, invasion and metastasis 36, 37 . In leukemias, it has been shown that PAI-2 is upregulated in M2 and M4-5 types, and is thought to be responsible for the invasive phenotype of these cells 23 . Consistent with these observations we have also shown that hematopoietic cells forced to express ZNF198/FGFR1 also up regulate PAI-2. In a recent report, PAI-2 was also shown to bind to the retinoblastoma (RB1) protein and protect it from degradation by an as yet unknown protease 26 . However, since PAI-2 was only detectable in the cytoplasm in the HEK-293 cells that expressed ZNF198/FGFR1, it is possible that its normal nuclear function is disrupted in these cells or it is also possible that the RB1 stabilizing function is performed by a protein other than PAI-2 in HEK-293 cells. Nevertheless, since PAI-2 also binds to the ZNF198/FGFR1 fusion protein in the cytoplasm, it is possible that, as for RB1, PAI-2 protects the fusion kinase from proteolysis. Thus, in MPD cells, preventing the degradation of ZNF198/FGFR1 may be an important mechanism for maintaining the malignant phenotype. In our studies, ZNF198/FGFR1 kinase is mostly sequestered to the cytoplasm, unlike ZNF198 which is present exclusively in the nucleus. The chimeric kinase has also lost the ability
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indicates that a stable expression of certain oncogenes may require proteins such as PAI-2 for specific and sustained induction of disease. Inhibition of uPA activity was assessed using the chromogenic assays as described in the methods section. Supernatants from cells showing forced expression of exogenous GFP or ZNF198 showed virtually undetectable inhibition of uPA activity. In contrast, supernatant from two different cell clones expressing the ZNF198/FGFR1 fusion kinase (FUS) show inhibition of uPA activity proportional to the levels of the input protein. 
